{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:52:34Z","timestamp":1793170354954,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"42","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The recurrence of clinically advanced cancers is an evolutionary consequence of standard-of-care chemotherapies generally administered at maximum tolerated doses to kill as many cancer cells as possible. The inevitable appearance of resistance raises the possibility of shifting treatment goals from complete tumor eradication to long-term disease control. The latter approach is employed by adaptive therapy, which aims to inhibit the evolutionary dynamics governing the spread of resistant tumor phenotypes. Adaptive therapy changes focus from the cancer cells that are responsive to therapy to those that are resistant and ultimately govern outcome. This therapeutic approach retains a pool of sensitive cancer cells to compete with the therapy-resistant ones through dynamic dose modulation and\/or timing. Thus, fluctuations of treatment-sensitive cells are used to control the resistant population and prolong tumor control with existing therapy agents. Here, we explore non-genetic mechanisms of resistance, including the protective role of the tumor stroma, the epithelial-to-mesenchymal transition, the overexpression of drug efflux pumps, and the extracellular vesicle-mediated transfer of them. These mechanisms can increase the size of the resistant population at the expense of the sensitive one, reducing the ability of adaptive therapy to force tumor evolution into controllable cycles.<\/jats:p>","DOI":"10.1038\/s41388-025-03582-y","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T15:57:33Z","timestamp":1758556653000},"page":"3999-4005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adaptive cancer therapy: can non-genetic factors become its achilles heel?"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-3529","authenticated-orcid":false,"given":"G\u00e1bor","family":"Valcz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1621-1510","authenticated-orcid":false,"given":"Robert A.","family":"Gatenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-2988","authenticated-orcid":false,"given":"Be\u00e1ta","family":"\u00dajv\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit I.","family":"Buz\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"3582_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","volume":"17","author":"RA Gatenby","year":"2020","unstructured":"Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol. 2020;17:675\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"3582_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","volume":"78","author":"JA Gallaher","year":"2018","unstructured":"Gallaher JA, Enriquez-Navas PM, Luddy KA, Gatenby RA, Anderson ARA. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 2018;78:2127\u201339.","journal-title":"Cancer Res"},{"key":"3582_CR3","doi-asserted-by":"crossref","unstructured":"Valcz G, Buz\u00e1s EI, Gatenby RA, \u00dajv\u00e1ri B, Moln\u00e1r B. Small extracellular vesicles from surviving cancer cells as multiparametric monitoring tools of measurable residual disease and therapeutic efficiency. Biochim Biophys Acta Rev Cancer. 2024;1879:189088.","DOI":"10.1016\/j.bbcan.2024.189088"},{"key":"3582_CR4","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69:4894\u2013903.","journal-title":"Cancer Res"},{"key":"3582_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20:743\u201356.","journal-title":"Nat Rev Cancer"},{"key":"3582_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/0008-5472.CAN-20-4079","volume":"81","author":"D Wodarz","year":"2021","unstructured":"Wodarz D. Adaptive therapy and the cost of drug-resistant mutants. Cancer Res. 2021;81:811\u20132.","journal-title":"Cancer Res"},{"key":"3582_CR7","doi-asserted-by":"publisher","first-page":"a040972","DOI":"10.1101\/cshperspect.a040972","volume":"10","author":"RA Gatenby","year":"2020","unstructured":"Gatenby RA, Brown JS. The evolution and ecology of resistance in cancer therapy. Cold Spring Harb Perspect Med. 2020;10:a040972.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3582_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtbi.2018.07.028","volume":"455","author":"J West","year":"2018","unstructured":"West J, Ma Y, Newton PK. Capitalizing on competition: an evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. J Theor Biol. 2018;455:249\u201360.","journal-title":"J Theor Biol"},{"key":"3582_CR9","doi-asserted-by":"publisher","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","volume":"8","author":"PM Enriquez-Navas","year":"2016","unstructured":"Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8:327ra24.","journal-title":"Sci Transl Med"},{"key":"3582_CR10","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1158\/0008-5472.CAN-12-2235","volume":"72","author":"AS Silva","year":"2012","unstructured":"Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012;72:6362\u201370.","journal-title":"Cancer Res"},{"key":"3582_CR11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","volume":"80","author":"J West","year":"2020","unstructured":"West J, You L, Zhang J, Gatenby RA, Brown JS, Newton PK, et al. Towards Multidrug Adaptive Therapy. Cancer Res. 2020;80:1578\u201389.","journal-title":"Cancer Res"},{"key":"3582_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/459508a","volume":"459","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA. A change of strategy in the war on cancer. Nature. 2009;459:508\u20139.","journal-title":"Nature"},{"key":"3582_CR13","doi-asserted-by":"crossref","unstructured":"Enriquez-Navas PM, Gatenby RA, 28 - evolutionary strategies to overcome cancer cell resistance to treatment in Phenotypic Switching. Academic Press. 2020;691-703.","DOI":"10.1016\/B978-0-12-817996-3.00028-1"},{"key":"3582_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017;8:1816.","journal-title":"Nat Commun"},{"key":"3582_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"JM Crook","year":"2012","unstructured":"Crook JM, O\u2019Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895\u2013903.","journal-title":"N Engl J Med"},{"key":"3582_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314\u201325.","journal-title":"N Engl J Med"},{"key":"3582_CR17","doi-asserted-by":"publisher","unstructured":"Hockings H, Lakatos E, Huang W, Mossner M, Khan MA, Metcalf S, et al. Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer. bioRxiv. 2023; https:\/\/doi.org\/10.1101\/2023.07.21.549688.","DOI":"10.1101\/2023.07.21.549688"},{"key":"3582_CR18","doi-asserted-by":"publisher","first-page":"e091262","DOI":"10.1136\/bmjopen-2024-091262","volume":"14","author":"UA Mukherjee","year":"2024","unstructured":"Mukherjee UA, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K, et al. Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer. BMJ Open. 2024;14:e091262.","journal-title":"BMJ Open"},{"key":"3582_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/bjc.2013.705","volume":"110","author":"AD Nygaard","year":"2014","unstructured":"Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET\/CT in patients with advanced NSCLC. Br J Cancer. 2014;110:363\u20138.","journal-title":"Br J Cancer"},{"key":"3582_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/10408363.2017.1299683","volume":"54","author":"M Oellerich","year":"2017","unstructured":"Oellerich M, Sch\u00fctz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, et al. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci. 2017;54:205\u201318.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3582_CR21","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1200\/JCO.2006.06.5599","volume":"24","author":"CC Jaffe","year":"2006","unstructured":"Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245\u201351.","journal-title":"J Clin Oncol"},{"key":"3582_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1148\/radiol.13122697","volume":"269","author":"RA Gatenby","year":"2013","unstructured":"Gatenby RA, Grove O, Gillies RJ. Quantitative imaging in cancer evolution and ecology. Radiology. 2013;269:8\u201315.","journal-title":"Radiology"},{"key":"3582_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7150\/thno.30309","volume":"9","author":"Z Liu","year":"2019","unstructured":"Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges. Theranostics. 2019;9:1303\u201322.","journal-title":"Theranostics"},{"key":"3582_CR24","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.3390\/cancers12123556","volume":"12","author":"E Hansen","year":"2020","unstructured":"Hansen E, Read AF. Modifying adaptive therapy to enhance competitive suppression. Cancers. 2020;12:3556.","journal-title":"Cancers"},{"key":"3582_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","volume":"122","author":"CC Bell","year":"2020","unstructured":"Bell CC, Gilan O. Principles and mechanisms of non-genetic resistance in cancer. Br J Cancer. 2020;122:465\u201372.","journal-title":"Br J Cancer"},{"key":"3582_CR26","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41568-024-00734-2","volume":"24","author":"L Laplane","year":"2024","unstructured":"Laplane L, Maley CC. The evolutionary theory of cancer: challenges and potential solutions. Nat Rev Cancer. 2024;24:718\u201333.","journal-title":"Nat Rev Cancer"},{"key":"3582_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/sj.bjc.6603024","volume":"94","author":"RM Glasspool","year":"2006","unstructured":"Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006;94:1087\u201392.","journal-title":"Br J Cancer"},{"key":"3582_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil ASA, et al. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl Oncol. 2024;39:101821.","journal-title":"Transl Oncol"},{"key":"3582_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665\u201374.","journal-title":"Nat Rev Cancer"},{"key":"3582_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366\u201381.","journal-title":"Nat Rev Clin Oncol"},{"key":"3582_CR31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.84263","volume":"12","author":"J West","year":"2023","unstructured":"West J, Adler F, Gallaher J, Strobl M, Brady-Nicholls R, Brown J, et al. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation. Elife. 2023;12:e84263.","journal-title":"Elife"},{"key":"3582_CR32","first-page":"409","volume":"3","author":"EC Fiedler","year":"2019","unstructured":"Fiedler EC, Hemann MT. Aiding and abetting: how the tumor microenvironment protects cancer from chemotherapy. Annu Rev Cell Biol. 2019;3:409\u201328.","journal-title":"Annu Rev Cell Biol"},{"key":"3582_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63518","volume":"10","author":"JP Capp","year":"2021","unstructured":"Capp JP, DeGregori J, Nedelcu AM, Dujon AM, Boutry J, Pujol P, et al. Group phenotypic composition in cancer. Elife. 2021;10:e63518.","journal-title":"Elife"},{"key":"3582_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/emph\/eoae021","volume":"12","author":"F Thomas","year":"2024","unstructured":"Thomas F, DeGregori J, Marusyk A, Dujon AM, Ujvari B, Capp JP, et al. A new perspective on tumor progression: Evolution via selection for function. Evol Med Public Health. 2024;12:172\u20137.","journal-title":"Evol Med Public Health"},{"key":"3582_CR35","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/ijms18071586","volume":"18","author":"DA Senthebane","year":"2017","unstructured":"Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi MAMA, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017;18:1586.","journal-title":"Int J Mol Sci"},{"key":"3582_CR36","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1158\/0008-5472.CAN-22-2217","volume":"82","author":"E Madan","year":"2022","unstructured":"Madan E, Palma AM, Vudatha V, Trevino JG, Natarajan KN, Winn RA, et al. Cell competition in carcinogenesis. Cancer Res. 2022;82:4487\u201396.","journal-title":"Cancer Res"},{"key":"3582_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","volume":"25","author":"F Klemm","year":"2015","unstructured":"Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198\u2013213.","journal-title":"Trends Cell Biol"},{"key":"3582_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cancers10120471","volume":"10","author":"G Yeldag","year":"2018","unstructured":"Yeldag G, Rice A, Del R\u00edo Hern\u00e1ndez A. Chemoresistance and the self-maintaining tumor microenvironment. Cancers. 2018;10:471.","journal-title":"Cancers"},{"key":"3582_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.trecan.2023.07.006","volume":"9","author":"M Kalli","year":"2023","unstructured":"Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. Beyond matrix stiffness: targeting force-induced cancer drug resistance. Trends Cancer. 2023;9:937\u201354.","journal-title":"Trends Cancer"},{"key":"3582_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3582_CR41","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/nm.3336","volume":"19","author":"WL Tam","year":"2013","unstructured":"Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19:1438\u201349.","journal-title":"Nat Med"},{"key":"3582_CR42","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","volume":"49","author":"W Lu","year":"2019","unstructured":"Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49:361\u201374.","journal-title":"Dev Cell"},{"key":"3582_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg R. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"3582_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2014.06.004","volume":"31","author":"M Cojoc","year":"2015","unstructured":"Cojoc M, M\u00e4bert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16\u201327.","journal-title":"Semin Cancer Biol"},{"key":"3582_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers10020052","volume":"10","author":"J Roche","year":"2018","unstructured":"Roche J. The epithelial-to-mesenchymal transition in cancer. Cancers. 2018;10:52.","journal-title":"Cancers"},{"key":"3582_CR46","doi-asserted-by":"publisher","first-page":"22986","DOI":"10.18632\/oncotarget.25184","volume":"9","author":"T Oba","year":"2018","unstructured":"Oba T, Ito KI. Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition. Oncotarget. 2018;9:22986\u20133002.","journal-title":"Oncotarget"},{"key":"3582_CR47","doi-asserted-by":"publisher","first-page":"37526","DOI":"10.18632\/oncotarget.6063","volume":"6","author":"SY Park","year":"2015","unstructured":"Park SY, Kim MJ, Park SA, Kim JS, Min KN, Kim DK, et al. Combinatorial TGF-\u03b2 attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget. 2015;6:37526\u201343.","journal-title":"Oncotarget"},{"key":"3582_CR48","doi-asserted-by":"publisher","first-page":"E188","DOI":"10.1002\/ijc.29158","volume":"136","author":"Y Kam","year":"2015","unstructured":"Kam Y, Das T, Tian H, Foroutan P, Ruiz E, Martinez G, et al. Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with \u201cersatzdroges. Int J Cancer. 2015;136:E188\u201396.","journal-title":"Int J Cancer"},{"key":"3582_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2789","volume":"10","author":"JI Fletcher","year":"2010","unstructured":"Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10:147\u201356.","journal-title":"Nat Rev Cancer"},{"key":"3582_CR50","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1158\/0008-5472.CAN-15-1337","volume":"75","author":"PM Enriquez-Navas","year":"2015","unstructured":"Enriquez-Navas PM, Wojtkowiak JW, Gatenby RA. Application of Evolutionary Principles to Cancer Therapy. Cancer Res. 2015;75:4675\u201380.","journal-title":"Cancer Res"},{"key":"3582_CR51","first-page":"3643","volume":"44","author":"JH Goldie","year":"1984","unstructured":"Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984;44:3643\u201353.","journal-title":"Cancer Res"},{"key":"3582_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3467","volume":"4","author":"AO Pisco","year":"2013","unstructured":"Pisco AO, Brock A, Zhou J, Moor A, Mojtahedi M, Jackson D, et al. Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nat Commun. 2013;4:2467.","journal-title":"Nat Commun"},{"key":"3582_CR53","first-page":"3352","volume":"5","author":"A Abolhoda","year":"1999","unstructured":"Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999;5:3352\u20136.","journal-title":"Clin Cancer Res"},{"key":"3582_CR54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","volume":"23","author":"EI Buzas","year":"2023","unstructured":"Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23:236\u201350.","journal-title":"Nat Rev Immunol"},{"key":"3582_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100833","volume":"62","author":"CPR Xavier","year":"2022","unstructured":"Xavier CPR, Belisario DC, Rebelo R, Assaraf YG, Giovannetti E, Kopecka J, et al. The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells. Drug Resist Updat. 2022;62:100833.","journal-title":"Drug Resist Updat"},{"key":"3582_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12140","volume":"10","author":"E\u00c1 T\u00f3th","year":"2021","unstructured":"T\u00f3th E\u00c1, Turi\u00e1k L, Visnovitz T, Cser\u00e9p C, M\u00e1zl\u00f3 A, S\u00f3dar BW, et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J Extracell Vesicles. 2021;10:e12140.","journal-title":"J Extracell Vesicles"},{"key":"3582_CR57","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41556-022-00983-z","volume":"24","author":"EI Buzas","year":"2022","unstructured":"Buzas EI. Opportunities and challenges in studying the extracellular vesicle corona. Nat Cell Biol. 2022;24:1322\u20135.","journal-title":"Nat Cell Biol"},{"key":"3582_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201609","volume":"9","author":"Q Yang","year":"2022","unstructured":"Yang Q, Xu J, Gu J, Shi H, Zhang J, Zhang J, et al. Extracellular vesicles in cancer drug resistance: roles, mechanisms, and implications. Adv Sci. 2022;9:e2201609.","journal-title":"Adv Sci"},{"key":"3582_CR59","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/leu.2009.76","volume":"23","author":"M Bebawy","year":"2009","unstructured":"Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia. 2009;23:1643\u20139.","journal-title":"Leukemia"},{"key":"3582_CR60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/ijo.2016.3509","volume":"49","author":"E Torreggiani","year":"2016","unstructured":"Torreggiani E, Roncuzzi L, Perut F, Zini N, Baldini N. Multimodal transfer of MDR by exosomes in human osteosarcoma. Int J Oncol. 2016;49:189\u201396.","journal-title":"Int J Oncol"},{"key":"3582_CR61","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1007\/s13277-014-2377-z","volume":"35","author":"MM Lv","year":"2014","unstructured":"Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, et al. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014;35:10773\u20139.","journal-title":"Tumour Biol"},{"key":"3582_CR62","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787\u201393.","journal-title":"N Engl J Med"},{"key":"3582_CR63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/255197a0","volume":"255","author":"J Cairns","year":"1975","unstructured":"Cairns J. Mutation selection and the natural history of cancer. Nature. 1975;255:197\u2013200.","journal-title":"Nature"},{"key":"3582_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23\u20138.","journal-title":"Science"},{"key":"3582_CR65","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/emph\/eoz018","volume":"2019","author":"R Gatenby","year":"2019","unstructured":"Gatenby R, Whelan C. Cancer treatment innovators discover Charles Darwin. Evol Med Public Health. 2019;2019:108\u201310.","journal-title":"Evol Med Public Health"},{"key":"3582_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188681","volume":"1877","author":"C Gedye","year":"2022","unstructured":"Gedye C, Navani V. Find the path of least resistance: adaptive therapy to delay treatment failure and improve outcomes. Biochim Biophys Acta Rev Cancer. 2022;1877:188681.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3582_CR67","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241264704","volume":"31","author":"Y Derbal","year":"2024","unstructured":"Derbal Y. Adaptive cancer therapy in the age of generative artificial intelligence. Cancer Control. 2024;31:10732748241264704.","journal-title":"Cancer Control"},{"key":"3582_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","volume":"48","author":"I Smalley","year":"2019","unstructured":"Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Eroglu Z, et al. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine. 2019;48:178\u201390.","journal-title":"EBioMedicine"},{"key":"3582_CR69","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76284","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Cunningham J, Brown J, Gatenby R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. Elife. 2022;11:e76284.","journal-title":"Elife"},{"key":"3582_CR70","unstructured":"https:\/\/www.clinicaltrials.gov\/study\/NCT05393791. Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03582-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:03:24Z","timestamp":1760393004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03582-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":70,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025,11,4]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03582-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}